title: [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
authors.forename: Laetitia
authors.initials: L
authors.lastname: Fartoux
authors.forename: Christèle
authors.initials: C
authors.lastname: Desbois-Mouthon
authors.forename: Raoul
authors.initials: R
authors.lastname: Poupon
authors.forename: Olivier
authors.initials: O
authors.lastname: Rosmorduc
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D045744:Cell Line, Tumor; D000068818:Cetuximab; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D004815:Epidermal Growth Factor / Q000502:physiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000502:physiology; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008024:Ligands; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D015398:Signal Transduction; D016211:Transforming Growth Factor alpha / Q000502:physiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008024:Ligands; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D016211:Transforming Growth Factor alpha; D004815:Epidermal Growth Factor; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000068818:Cetuximab; D000077156:Gefitinib